AGENUS INC Finite-Lived Intangible Asset, Expected Amortization, Year One
AGENUS INC (AGEN) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $300.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $300.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $300.00K.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $300.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $300.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One | Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed |
|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $300.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $300.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $300.00K 10-K · filed 2025-03-17 | |
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $500.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $500.00K 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $600.00K 10-K · filed 2024-03-14 | |
| 2023-09-30 | $500.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $600.00K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $600.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.70M 10-K · filed 2023-03-16 | |
| 2022-09-30 | $1.80M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.80M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $2.20M 10-K · filed 2022-03-01 | |
| 2021-09-30 | $2.20M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $2.20M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $2.20M 10-Q · filed 2021-05-07 | |
| 2020-09-30 | $2.20M 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $2.20M 10-K · filed 2021-03-16 | $1.90M 10-K · filed 2020-03-16 |
| 2018-12-31 | $1.90M 10-K · filed 2019-03-18 | |
| 2017-12-31 | $2.00M 10-K · filed 2018-03-16 | |
| 2016-12-31 | $2.20M 10-K · filed 2017-03-16 | |
| 2015-12-31 | $2.20M 10-K · filed 2016-03-15 | |
| 2015-06-30 | $533.00K 10-Q · filed 2015-08-03 | |
| 2015-03-31 | $517.00K 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $528.00K 10-K · filed 2015-03-16 | |
| 2014-09-30 | $549.00K 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $586.00K 10-Q · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |